Could a new mechanism change how we target prostate cancer?

Live from #ESMO2026, Dr. Ben Garmezy joins Brian and Tom to discuss Phase 1 data on RIPTAC, a novel approach that uses the androgen receptor (AR) to target BRD4 and disrupt cancer cell transcription.

🎙️ Episode 524 of The Uromigos Podcast is now live: https://bit.ly/4z6zWaG

#Uromigos #ProstateCancer #GUOncology